145 results about "Hyperlipidemia" patented technology

The invention provides application of qi and blood strengthening oral liquid in preparation of a medicine for improving hyperlipidemia, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by means of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood is high in content of effective components, and has a good effect on consolidating qi and blood. The oral liquid for consolidating qi and blood can significantly improve hyperlipidemia, and has potential clinical application value.

Disclosed herein are compositions and methods for the modulation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) expression, wherein the compositions include an siRNA duplex or a conjugated siRNA duplex. Also disclosed herein are methods, and compositions for use in methods, of treating age-related macular degeneration (AMD) or hyperlipidemia. The compositions disclosed herein comprise an siRNA duplex that comprises a sense sequence and an antisense sequence, wherein the sense sequence and the antisense sequence are at least partially complementary to each other.

This invention discloses a fermented traditional Chinese medicine for treating hyperlipidemia, its preparation method, and its application, relating to the field of traditional Chinese medicine. This fermented traditional Chinese medicine is prepared using Bacillus sp. JQ.Y-1, which was deposited on June 24, 2021, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M2021761. The fermented traditional Chinese medicine provided by this invention offers a new alternative drug for the treatment of hyperlipidemia of the dampness-obstruction type in the middle jiao (middle burner). It has a significant lipid-lowering effect, is safe and reliable, can regulate intestinal flora, protect the liver and kidneys, and has no side effects.

The invention discloses white paeony root polysaccharide with a blood fat reducing function as well as a preparation method and application of the white paeony root polysaccharide. The radix paeoniae alba polysaccharide with the blood fat reducing function is extracted from radix paeoniae alba for the first time, and cell experiments prove that the polysaccharide has the effect of reducing lipid generation in a high-fat cell model; further animal model experiments prove that the polysaccharide can also achieve the blood fat reducing effect in a hyperlipidemia animal model, it is proved that the polysaccharide can be used for preparing the blood fat reducing medicine, and the polysaccharide belongs to natural ingredients and is high in safety and wide in application prospect.

The invention provides antisense oligonucleotide aiming at a Sptbnl target spot and application of the antisense oligonucleotide. The antisense oligonucleotide can be used for knocking down the expression of Sptbnl, and in-vivo and in-vitro experiments find that the antisense oligonucleotide can be used for treating hyperlipidemia and NASH and can also be used for treating neovascular eye diseases.

The present invention relates to a pharmaceutical composition which does not undergo rapid initial burst release of a drug by comprising sustained release microspheres consisting of texipatide or a pharmaceutically acceptable salt thereof, an initial burst release inhibitor, and a biodegradable polymer, has a high drug content with respect to particle size, and has high bioavailability, thus, the composition can minimize patient pain and inflammatory response that may occur when administered to a human body, and thus can be effectively used in the prevention or treatment of diabetes, beta cell dysfunction, hypertension, hyperlipidemia, obesity, and non-alcoholic steatohepatitis.

The invention relates to the technical field of functional food, in particular to a tartary buckwheat and roxburgh rose composition for regulating blood pressure and blood fat and a preparation method thereof. The tartary buckwheat and roxburgh rose composition comprises tartary buckwheat and roxburgh rose. The mass ratio of the tartary buckwheat to the roxburgh rose is 1: (1-3). In-vitro activity evaluation, cell experiments and animal experiments prove that flavonoid compounds of tartary buckwheat and active ingredients such as vitamin C of roxburgh rose in the composition generate a synergistic effect, so that the antioxidant capacity, the ACE inhibition rate, the cholesterol clearance rate and the pancreatic lipase inhibition rate can be remarkably improved, NO generation is effectively promoted, and the curative effect is good. The contents of TC, TG and LDL-L are reduced, the HDL-L level is increased, and the balance of vascular active substances is regulated. The raw materials are all medicinal and edible, are high in safety and free of side effects, provide a natural and efficient auxiliary conditioning scheme for chronic metabolic diseases such as hypertension and hyperlipidemia, and have a good industrialization prospect.

The invention provides application of ginkgo terpene lactones, bilobalide or stereoisomers thereof in preparation of drugs for preventing or treating hyperlipidemia and hyperlipidemia complications.

This invention discloses an octapeptide derived from soybean protein with the function of lowering blood pressure, blood sugar, and cholesterol, as well as its preparation and application, belonging to the field of small molecule peptide technology. The octapeptide sequence is YEGNWGPL, which can be obtained artificially or by targeted enzymatic hydrolysis of soybean protein isolate. Functional verification in a hyperlipidemia model shows that the octapeptide YEGNWGPL has the function of lowering blood lipids; functional verification in a hyperglycemia model shows that the octapeptide YEGNWGPL has the function of lowering blood sugar, with a significantly better effect than the drug metformin; functional verification in a hypertension model shows that the octapeptide YEGNWGPL has the function of lowering blood pressure, with a significantly better effect than the antihypertensive drug captopril; moreover, food-derived bioactive peptides have high biosafety, therefore, they can be applied to the development of related products for lowering blood pressure, blood sugar, and cholesterol or assisting in lowering blood pressure, blood sugar, and cholesterol, with good market prospects and application potential.

The invention discloses application of lactobacillus fermentum E1 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus fermentum E1 disclosed by the invention can remarkably promote fat metabolism in the zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in the hyperlipidemia zebra fish body, and has the potential of being applied to losing weight and regulating the blood fat level; theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by using the lactobacillus fermentum E1.

The invention discloses application of knockout or inhibition of intestinal epithelium Ufbp1 gene expression in preparation of medicines for preventing and / or treating obesity, and belongs to the technical field of biological medicines. In order to solve the problems of limited effect, many side effects and the like of the existing obesity treatment means, the invention provides Ufbp1 specifically expressed by intestinal epithelial cells as a new anti-obesity intervention target for the first time. By knocking out or inhibiting intestinal epithelium Ufbp1, weight gain, adipose tissue accumulation, hyperlipidemia, liver fatty degeneration and insulin resistance induced by high fat diet can be effectively resisted. The action mechanism is related to influence on secretion of intestinal apolipoprotein ApoB48 / ApoA1 and further regulation and control of whole body lipid metabolism. The invention provides a clear target and theoretical basis for developing novel anti-obesity therapies such as small-molecule inhibitors and nucleic acid drugs of targeted intestinal epithelium Ufbp1, and has important clinical transformation prospects.

The invention provides a traditional Chinese medicine composition which comprises the following components in parts by weight: 32-34 parts of rumex hanus, 20-31 parts of dandelion, 20-32 parts of uncaria rhynchophylla and 15-35 parts of gastrodia elata. And at least one of the following six traditional Chinese medicines in parts by weight: 17-37 parts of radix paeoniae alba, 15-20 parts of lumbricus, 10-45 parts of eucommia ulmoides, 22-34 parts of longan seeds, 20-37 parts of tribulus terrestris and 10-30 parts of herba siegesbeckiae. The traditional Chinese medicine composition is taken by adopting deuterium-depleted water. The combination of the traditional Chinese medicinal materials has a synergistic effect in the aspects of treating hypertension, hyperlipidemia and metabolic syndrome, the traditional Chinese medicinal materials respectively contain different active ingredients, the overall curative effect is enhanced by regulating blood pressure, blood fat and metabolic functions through multiple targets, and in order to enable the traditional Chinese medicinal composition to better exert the drug effect, the traditional Chinese medicinal composition has a remarkable curative effect. Preferably, the deuterium-depleted water is matched with the traditional Chinese medicine composition to be taken, and the effect of the deuterium-depleted water is developed by 1-2 times.

The present application relates to a new use of Fuling Gancao Decoction, and specifically discloses application of Fuling Gancao Decoction in treatment of hyperlipidemia, wherein the Fuling Gancao Decoction is composed of the following components in parts by weight: Fuling 2 parts, Guizhi 2 parts, Zhigancao 1 part and Shengjiang 3 parts. It is found through animal experiment research that the Fuling Gancao Decoction can improve the symptoms of hyperlipidemia rats, reduce the content of TG, TC and LDL-C in serum, improve the liver lipid, blood sugar of hyperlipidemia model animals, reduce the liver coefficient, improve the liver cell fatty degeneration, reverse the pathological morphology of adipose tissue cells and the mitochondrial damage of hyperlipidemia model animals. A new indication of the Fuling Gancao Decoction is found, the development of traditional Chinese medicines is promoted, and a new drug composition with less side effects is provided for treatment of hyperlipidemia.

The invention relates to the technical field of traditional Chinese medicine compositions, and discloses a traditional Chinese medicine composition for athletes and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises 4 parts of ginseng, 8 parts of polygala tenuifolia, 20 parts of Chinese yam, 12 parts of bighead atractylodes rhizome, 4 parts of pseudo-ginseng, 15 parts of rhizoma polygonati, 12 parts of flax seed, 10 parts of wolfberry, 15 parts of radix ophiopogonis, 15 parts of prepared rehmannia root, 15 parts of prepared fleece flower root, 15 parts of longan aril, 10 parts of mulberry leaf, 12 parts of wild chrysanthemum flower, 10 parts of eucommia ulmoides, 12 parts of rhizoma cibotii, 12 parts of cortex acanthopanacis and 12 parts of radix achyranthis bidentatae. According to the traditional Chinese medicine composition for the athletes and the preparation method of the traditional Chinese medicine composition, the composition of a decoction formula and a beverage formula can help the athletes to accelerate elimination of exercise-induced fatigue, improve mental functions and enhance physique, physical strength, intelligence and memory; the composition of the weight-losing formula definitely provides a conditioning scheme for hyperlipemia obesity, obesity due to spleen deficiency and obesity due to qi deficiency.

Provided are a traditional Chinese medicine composition for lipid reduction, a preparation method therefor, and use thereof. The traditional Chinese medicine composition comprises a lipid-reducing core component and auxiliary components. The lipid-reducing core component is composed of Mallotus oblongifolius and Dalbergiae Odoriferae Lignum, and the auxiliary components comprise Crataegi fructus and Salviae miltiorrhizae. The traditional Chinese medicine composition can ameliorate the hyperlipidemia condition and reduce the body weight of model animals, and can also reduce the expression of various inflammatory factors.

The invention relates to associated faecalis and application thereof, the associated faecalis is preserved in Guangdong Microbial Culture Collection Center on November 10, 2025, and the preservation number is GDMCC No: 67255. The strain is high in self-aggregation capability, beneficial to adhesion to intestinal tracts and high in customization capability; the strain shows a good safety characteristic and has relatively strong gastrointestinal tract environment adaptability; the strain has remarkable antioxidant activity; the strain can generate gamma-aminobutyric acid, is helpful for improving the metabolic state of a host and regulating the neurological function, and has the probiotic effects of regulating lipid, resisting inflammation and improving the metabolic state of the host, namely improving sleep; besides, the bile salt hydrolase of the strain is remarkable in activity, contributes to bile acid metabolism and promotion of cholesterol excretion, has the effects of reducing and regulating blood fat, and can improve obesity, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease.

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

The invention discloses a method for extracting 7-hydroxy-8-O-beta-D-glucopyranoside-coumarin from apple peel, a compound extracted by the method and application of the compound. The invention belongs to the field of extraction and separation of natural products, and relates to a coumarin compound found in apple peel. The invention further provides a separation and identification method of the novel compound. Methanol extraction, ethyl acetate elution and a high performance liquid chromatograph are sequentially adopted for separation, purification and preparation. The structure of the compound is determined to be the compound found in apple peel for the first time by adopting nuclear magnetic identification of hydrogen spectrum and carbon spectrum. The compound has a protective effect on vascular endothelial dysfunction caused by hyperlipidemia, has no toxic effect on cells, and can be used as a raw material for drug development and pharmacological activity research.

The invention relates to the technical field of traditional Chinese medicine (homology of medicine and food) compositions, and discloses a composition with a function of reducing blood pressure and blood fat. Comprising the following components in parts by weight: 3-9 parts of gastrodia elata, 5-15 parts of folium cortex eucommiae, 9-12 parts of hawthorn, 5-10 parts of folium mori, 6-12 parts of chrysanthemum, 9-15 parts of semen cassiae, 1-3 parts of red yeast rice, 3-9 parts of radix angelicae, 9-15 parts of radix rehmanniae, 6-12 parts of angelica sinensis, 3-6 parts of American ginseng, 6-12 parts of dendrobium officinale, 3-10 parts of lucid ganoderma, 1-2 parts of stigma croci, 1-3 parts of cordyceps sinensis, 5-10 parts of sophora flower bud and 1-3 parts of earthworm protein. According to the composition with the function of reducing blood pressure and blood fat as well as the preparation method and the application of the composition, the composition can obviously reduce the content of cholesterol and triglyceride in blood, has the effects of reducing blood pressure and blood fat, and can be used for preparing medicines or functional foods for treating hypertension and hyperlipidemia.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

The invention relates to a preparation method of sugar-free hawthorn and poria cocos granules. The sugar-free hawthorn and poria cocos granules comprise the following raw materials: poria cocos, scorched hawthorn and coix seeds. The sugar-free auxiliary material is one or two or more of mannitol, erythritol and maltitol. The sugar-free hawthorn and poria cocos granules meet the requirements of patients with diabetes mellitus, obesity, hyperlipidemia, coronary heart disease and the like on forbidding to eat sugar, and the clinical application range is widened.

The invention discloses a roxburgh rose lactic acid bacteria solid beverage and application thereof in preparation of foods, health-care products or medicines for reducing hyperlipidemia, preventing colitis and resisting oxidation, and belongs to the field of probiotic health-care foods. The rosa roxburghii tratt lactic acid bacteria solid beverage is prepared from plant lactobacillus R-15, rosa roxburghii tratt fine powder, mannan oligosaccharide, resistant dextrin, coix lacryma-jobi extract, hawthorn extract, silicon dioxide and the like. The rosa roxburghii tratt lactobacillus solid beverage can significantly reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in the liver and serum of a mouse, inhibit fatty degeneration of the liver, and inhibit colitis induced by high fat diet. The invention has important application value in prevention and treatment of hyperlipidemia and colitis.

This invention discloses a dosage analysis method for anesthetic drugs during surgery in patients with hypertension, hyperlipidemia, and hyperglycemia. This method integrates multi-source heterogeneous health data from the patient over the past five years to construct a personalized, structured health record. During anesthesia induction, based on the patient's individualized pharmacokinetic model and assessed drug interaction risks, it calculates and recommends precisely adjusted induction doses. During anesthesia maintenance, it innovatively decodes specific EEG signals to establish a dynamic mapping relationship between neurophysiological characteristics and pharmacokinetics. Based on EEG characteristics reflecting drug sensitivity and pain perception, it automatically and in real-time adjusts the predicted concentration of the target drug, achieving closed-loop precise control based on direct feedback from the central nervous system. The system automatically identifies all medications used by the patient, generates a drug interaction risk assessment report using a massive knowledge base, and dynamically updates the risk level and sends warnings during surgery based on real-time vital signs.

The present invention includes methods of using improved compositions and improved compositions comprising thermally stable plant juice soluble vegetable proteins for resisting pathogenic effects; the improvements include that the composition comprising heat stable plant juice soluble vegetable proteins is essentially a water insoluble concentrated substance free of components that are more soluble in plant juice, and is enriched in heat stable proteins of plant juice; dosage forms prepared from the composition are useful for adiponectin agonist action for reducing the risk of one or more conditions selected from the group consisting of type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity, and are useful for antimicrobial action for reducing the risk of one or more conditions selected from the group consisting of type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity. The present invention relates to antimicrobial agents for reducing the risk of or treating microbial infections in plants and animals with or without synergy with other antimicrobial agents. The present invention includes a composition substantially characterized by the infrared absorption spectrum provided in the present invention.

The invention discloses application of lactobacillus gasseri LS03 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus gasseri LS03 disclosed by the invention can remarkably promote fat metabolism in a zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in a hyperlipidemia zebra fish body, has the potential of being applied to losing weight and regulating the blood fat level, and can be used for preventing and treating hyperlipidemia. The lactobacillus gasseri LS03 provides theoretical reference and guidance basis for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by utilizing the lactobacillus gasseri LS03.

This invention belongs to the field of traditional Chinese medicine technology. More specifically, it relates to the application of a processed product of Citrus reticulata peel or Citrus reticulata peel embryo (with bitterness removed) in the preparation of products for lowering lipids and preventing and treating hyperlipidemia. Compared with the original product, the processed product of Citrus reticulata peel or Citrus reticulata peel embryo provided by this invention significantly reduces bitterness while significantly enhancing its effects in lowering cholesterol and triglycerides and regulating blood lipids. This processed product helps maintain normal levels of serum cholesterol, triglycerides, and low-density lipoprotein, and can significantly improve liver damage caused by hyperlipidemia, thus having important application value in lowering lipids and protecting the liver.

The invention provides a prepared rheum tanguticum extract obtained by a specific method, and the prepared rheum tanguticum extract containing 14 specific compounds is obtained by adopting a macroporous resin adsorption method, taking anthraquinone glycoside as an index and determining optimal purification process conditions through a single factor test. The effects of preventing, treating, improving, controlling or relieving hyperlipidemia, dyslipidemia and obesity and / or improving lipid metabolism are verified.

The invention relates to the field of microorganisms, and discloses application of aspergillus cristatus in preparation of a medicine for preventing and / or treating hyperglycemia and / or hyperlipidemia, and the preservation number of the aspergillus cristatus is CGMCC No.41727. The aspergillus cristatus provided by the invention can degrade cholesterol, has the activity of degrading cholesterol and sugar-related enzymes, can relieve the symptoms of hyperlipidemia and hyperglycemia of high-fat diet mice, and has an application prospect in drugs for preventing and / or treating hyperglycemia and / or hyperlipidemia.

This invention relates to the biomedical field, specifically to biomarkers, kits, and their applications for assessing immune dysfunction in HIV-infected individuals. This invention discloses the application of the molecular marker SMPD1 and / or substances that detect said molecular marker in the assessment, auxiliary assessment, screening, and risk stratification of immune dysfunction in HIV-infected patients with hyperlipidemia. This invention is the first to identify an immunometabolic paralysis subtype in HIV-infected individuals with hyperlipidemia. SMPD1 expression was significantly upregulated in these subtype patients, and its high expression was significantly associated with the risk of immune reconstitution failure. A combined diagnostic model based on SMPD1 and triglycerides demonstrated excellent diagnostic efficacy. Therefore, substances that detect SMPD1 can be used for the assessment and risk stratification of immune dysfunction in HIV-infected patients with hyperlipidemia. This invention provides an effective tool for the early identification and risk stratification of these patients and has broad clinical application prospects.

The application discloses an application of lactobacillus reuteri BNCC186563 in prevention and improvement of related diseases caused by high-fat diet and belongs to the technical field of microorganisms. It is found that the lactobacillus reuteri BNCC186563 can synergistically activate a PPAR alpha signal pathway and remodel a glycerophospholipid metabolism network, and the lactobacillus reuteri BNCC186563 can be used as a potential medicine, health care product and functional food for preventing and improving related diseases caused by high-fat diet, such as obesity, impaired glucose tolerance, insulin resistance, abnormal lipid metabolism, liver lipid accumulation, liver damage, inflammation and hyperlipidemia.